| Name | LY3200882 |
| Description | LY3200882 is a highly selective inhibitor of TGF-β receptor type 1 (TGFβRI). |
| In vitro | LY3200882 effectively inhibits TGFβ-mediated SMAD phosphorylation in tumor and immune cells in vitro, demonstrates anti-metastatic activity in migration assays, and rescues TGFβ1 or T regulatory cell-suppressed naive T cell activity, restoring proliferation in immune suppression assays [1]. |
| In vivo | LY3200882 potently inhibits TGFβ mediated SMAD phosphorylation in vivo in subcutaneous tumors in a dose-dependent fashion. LY3200882 has shown anti-metastatic activity in vivo in an experimental metastasis tumor model (intravenous EMT6-LM2 model of triple negative breast cancer) [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 4.36 mg/mL (10.01 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (2.3 mM), Sonication is recommended.
|
| Keywords | Transforming growth factor beta receptors | TGF-βRI (ALK5) | TGFβRI | TGF-β/Smad | TGF-β Receptor | TGFβ | TGFbeta/Smad | TGF-beta | TGFbeta | TGF-b/Smad | TGFb | Smad | serine-threonine | phosphorylation | LY-3200882 | LY3200882 | LY 3200882 | Inhibitor | inhibit | immune | ATP-competitive | anti-metastatic | Anti-cancer | ALK5 |
| Inhibitors Related | Trimethylamine N-oxide | Melamine | SB-431542 | Hydrochlorothiazide | Hippuric acid | Chromenone 1 | Pirfenidone | A 83-01 | Suberic acid | Cetrimonium bromide | Galunisertib | Alantolactone |
| Related Compound Libraries | Highly Selective Inhibitor Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | TGF-beta/Smad Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |